China animal vaccine market 50 million dollar gamble

The rivers and lakes big guy's every move, may mean the surging. Since late May, Harbin Pharmaceutical Group and Pfizer's pig asthma vaccine trade has been highly concerned about the industry. June 10, Harbin Pharmaceutical Group also held a special media conference. For a time, the spotlight shone like the sun.　　The major media are basically fired again. Into the July, the noise seemed to calm down.　　Harbin Pharmaceutical Group spokesman Gao also modestly to the Southern Country newspaper reporter said, now this matter is not news.　　However, the southern Rural newspaper reporter found that as the Chinese animal vaccine market in a rare gamble, the hand has only just begun. Pfizer has integrated resources to promote new products Harbin drug borrowing channel effect or limited July 8, farmers Lao Yang attended the Pfizer company in Foshan, a product promotion meeting.　　He was surprised to find that this would be mainly to promote asthma Miorifut (RESPIFENDRMH), Juffoute is the original Fu Tao Company (Wyeth) products.　　After listening to the introduction, Lao Yang just know, the original Wyeth company was bought by Pfizer, and Pfizer's asthma Miaori times, Rui times suitable-Wang has been sold to Harbin Pharmaceutical Group. Lao Yang is Pfizer's old customers, has been using its asthma Miaori times suitable, is very familiar with the red.　　Lao Yang Some doubt, in the end is to listen to Pfizer technical staff, replaced by Juffoute, or use the original Rui times suitable. He picked up the publicity material to study carefully and immediately found the subtleties. In Juffoute's function introduction, specially marked: "Does not excite the pig circovirus".　　Lao Yang immediately smiled, this is not the right to be accused of the flaw? Old Yang and side of the peer exchange for a moment, both people think it is very interesting. When Pfizer used to promote the company, it had other companies ' technicians claiming that "this product is not conducive to the use of the disease in the context of the ring virus, or even easy to stimulate the disease", and Pfizer's technicians dismissed as "rival defamation."　　Now, Pfizer sold them, to promote the Juffoute of the original Fu Road Company, do not know whether intentionally or unintentionally, the instructions appear to imply something.　　"Really then WTF," Yang decided, Pfizer's technical service is strong, for the sake of insurance, or to follow Pfizer's better.　　It is understood that similar to such technology promotion and product promotion, Pfizer is launching, its purpose is very simple, despite the hard cultivation of the series is stripped out, but they hope to rely on Pfizer resources, to expand Juffoute market share.　　Reseller Ahan has also been watching the developments recently. Ahan Agent Pfizer products have a short time, recently, he encountered a small confusion. Pfizer is trying to publicize the Juffoute series, hoping to persuade the original customers to change their products. But for what reason is the farmer persuaded? Ahan feel, not too utilitarian, just let go, it is straightforward to say that the original product is not good, will give customers a bad impression.　　What's more, many dealers, including him, are also acting on both sides of the product. It is understood that at present, Harbin Medicine borrowed Pfizer's distribution channels, dealers can also sell the series andJuffoute series. Ahan firmly believe that, at least in the next 3 years, the two products are produced by Pfizer company, from the quality itself, Rui-Times Fitness series and the series are good, but also have customer groups. Standing in the position of the dealer, he would prefer to maintain the status quo, that is, the sale of Pfizer and Harbin Medicine two sets of products. "No one has too many options. "So far, Pfizer has not asked him to distribute Juffoute. He is not sure whether this state will change in the future.　　However, as Pfizer's fully-supported dealer, Ahan admits, Pfizer's strength, once Pfizer's strategy to adjust, he must follow.　　According to industry sources, since September 2009, the Ministry of Commerce ruled that the Pfizer company in China to peel off the appropriate business, Pfizer has begun large-scale adjustment dealers, for the new business to do bedding. Bo Mei Animal Drugs company technical Director Long Jianyong originally Agent Fu Road Company's vaccine, at the end of last year he was the Pfizer company excluded from the new distributor group.　　He to the Southern Country newspaper reporter analysis, Pfizer existing channels even by the HA Medicine borrowed, the effect will not be too good, because Pfizer to promote their own Juffoute, will inevitably to their own support dealers do certain requirements. Dr. Shao of the Institute of Veterinary Medicine of Jiangsu Academy of Agricultural Sciences is an expert in research on swine asthma vaccine, and he analyses the industry's recognition that Pfizer's success lies mainly in its strong marketing team and service capabilities, although it can borrow Pfizer's channels, but as Pfizer pushes its own products,　　Its marketing team and service capacity is unlikely to be used for Harbin medicine, on the contrary, two of them will be secretly competing, and Kazakhstan medicine is likely to be a disadvantage. According to the Ministry of Commerce published data, Juffoute products accounted for 11.4% of China's market share, only in the series and the British Granville products.　　A dealer even believes that, as far as he understands, Juffoute's products complaints to be lower than the Swiss-times, and the things that Pfizer stripped out, in fact, have already fallen in market share.　　It will take 10 years to recover the investment. Is it a losing business? June 10, in the media to explain the meeting, Harbin Pharmaceutical Biological Vaccine Co., Ltd. General manager Han Yu confidence hundred Zhang. "We are fully confident that we have the ability to develop and expand the development of two high-end animal vaccine products in mainland China, and to achieve innovation on the basis of fully digesting and absorbing advanced technology," he said in his speech. "It is understood that Harbin Pharmaceutical Group's Harbin Pharmaceutical Biological Vaccine Co., Ltd. is China's animal vaccine industry, one of the strong manufacturers, mainly concentrated in poultry vaccines." A research report from the Shuiqingmuhua Research Center suggests that 2009 China's animal vaccine market is about 6.2 billion yuan, ranked the top five companies market share, 30%, Qingdao Yi Bang 13.4%, Jinyu group 9.1%, Harbin Medicine vaccine 8%, Tian Kang biological 6.2%, Chengdu days State 1.2%,　　Other companies accounted for 32.1%. This means that even without the pig vaccine, Harbin Pharmaceutical Group has a relatively large market share, if the market to enter a larger pig vaccine, Harbin Medicinewill be stronger.　　However, the reporter found in the interview, for the 50 million dollar deal, most of the industry said that the price is too high, far beyond the value of the merits of the Swiss. One of the stories circulating in the industry is very good testimony to this view: in the final bid for the four companies, the Chinese pastoral shares bid for 30 million yuan/year, according to 3 years for 90 million yuan, less than the price of Harbin Medicine bid 1/3.　　The stock is the general agent of Pfizer in China, the relationship between the two sides close, the industry originally thought that the company will spend the flowers and grazing, but the result is surprising. "Although Kazakhstan has money, it is a sky-high deal," he said.　　Shao very frankly. Nanjing Tian Bang Guangdong technical director Cao Haitao said, he contacted most people feel, "ha medicine too rich, incredibly dig so much money to buy Rui times."　　"Pfizer dealer Ahan also admits that Kazakhstan's drug 50 million dollars, far beyond his expectations, people surprised." It is understood that, although mycoplasma pneumonia in the domestic pig incidence rate reached 90%, but because the disease does not directly lead to serious pig death, so farmers do not attach great importance to it. In recent years, the growing complexity of swine disease, blue ear disease, foot-and-mouth diseases, swine fever and other large outbreaks of disease, containing farmers ' energy and input costs, the vast majority of pig farms are not willing to play expensive pig asthma seedlings.　　Harbin Pharmaceutical Group general manager Jiang Linque in the media interview also confessed that only 6% of domestic pigs vaccinated pig asthma vaccine. The Ministry of Commerce, in its 2009 77th Bulletin, said Pfizer's Rui-times and Rayleigh-Mong accounted for 38% of China's market share, much higher than other manufacturers ' vaccines (the second one was Invista, accounting for 18.35%).　　According to media reports, Pfizer's 2009-year asthma vaccine sales of more than 70 million yuan to push back, the domestic pig asthma cake only about 200 million yuan. Most people interviewed by reporters believe that the reason for the extraordinary high market share is not that this product is particularly excellent, but the Pfizer's marketing team and service capabilities. Once the Kazakh drug takes over, its market share is likely to fall sharply.　　Even if it keeps 70 million yuan in sales, and earns 35 million yuan a year in terms of 100% of its profit, it will take about 10 years to earn only a 50 million dollar bid.　　Long Jianyong also believe that the current pig price is not good, farmers are careful, not willing to hit the vaccine, Kazakhstan drug election at this time, not a good time, the market may have a huge change.　　What exactly do you want to buy?　　50 million dollars in advertising? No one in the world is going to be a sucker for nothing.　　If the asthma vaccine itself is not as big as people think, what is it buying? July 9, the reporter contacted Pfizer China headquarters and Harbin Pharmaceutical Group. Pfizer's China headquarters declined to be interviewed. Harbin Pharmaceutical Group spokesman Gao also said that the relevant person is in the United States business trip, to the relevant responsible person will contact reporters after returning.　　As of the manuscript version, Harbin Medicine did not reply to the relevant mail. The reporter interviewed a lot of linesIndustry, all sorts of ideas seem plausible, but they all stop at guessing.　　One view is that Harbin Medicine is looking to buy Pfizer's production technology. It is understood that because of asthma inactivated vaccine and its adjuvant production technology is relatively high, the development of a new vaccines need 3-10 years time, there is no domestic manufacturers, the market is basically seven or eight foreign brand monopoly.　　The only company to get asthma vaccine approval of the factory is in Nanjing days, belong to the weak poison seedlings, need to chest injection, and the foreign brands only need intramuscular injection, so the domestic weak poison vaccine by some farmers think more trouble. Although the market of asthma seedlings is not big, but the price is not expensive, each pig generally need to invest 7-8 yuan, the factory profit is more abundant, so ha medicine fancy this market potential.　　Pfizer's market share of the series is quite high, and its adjuvant Efikin is a more distinctive patented product, the production technology is worth the study of Harbin Medicine, and may be used in the production of other products.　　In the June 10 media presentation, Harbin Pharmaceutical Group general manager Jiang Linque has expressed the meaning of the media, he said, the domestic research and development capabilities and foreign gaps, Harbin Medicine is to save research and development and explore the market time.　　Another point of view, ha medicine is not to see the asthma market, but the whole pig vaccine market, want to use Pfizer's strength to enter. Harbin Pharmaceutical Biological Vaccine Co., Ltd. is one of the sentinel production enterprises in China, the business is mainly concentrated in the poultry seedlings, for the market huge pig vaccine has not been deeply involved.　　If the drug can use Pfizer's mature channels and products to enter the market once and for all, is undoubtedly opened a new blue ocean. Vaccine market is a policy-oriented market. According to related industry reports show that 2009 China's animal vaccine market about 6.2 billion yuan, of which the state compulsory vaccine accounted for more than 86%. Of the four compulsory immunization vaccines that the government buys, only the avian influenza vaccine belongs to poultry, and swine fever, foot-and-mouth disease, and highly pathogenic blue-ear vaccine all belong to swine vaccine. Harbin Group, which has only been involved in the production of the avian flu vaccine, has already accounted for 8% of the market, and must enter the pig vaccine field if it is to get a bigger cake.　　The drug hit 50 million dollars to buy Pfizer's asthma production technology, not only a beautiful advertising campaign, but also won a ticket to another high threshold market.　　Another view is that the drug may be in preparation for the injection of shares in the listed companies, so it may be a capital game to buy it. It is reported that Harbin Pharmaceutical Group has promised, February 2011 ago, to its own listed company Harbin Pharmaceutical shares injected not less than 2.611 billion yuan of assets. This is a good news for listed companies.　　At present, Harbin Pharmaceutical Biological Vaccine Co., Ltd. is not yet part of Harbin Pharmaceutical shares, many analysts speculated that Harbin drug acquisition Pfizer's pig vaccine, but in the expansion of the vaccine business, good packaging into Harbin Pharmaceutical shares, for listed companies to add some hype concept and content.　　However, although a lot of financial media are asking this question, in the media to explain the meeting, Harbin Pharmaceutical Group general manager Jiang Linque declined to answer politely. SpanishQin Yun, general manager of the company's China area, thinks that the industry has a variety of views that are normal, but not very important. "Since Kazakhstan is willing to pay for the money, it means that the deal is worth so much money for the moment," he said. Trading is expensive and cheap, only the future can see clearly. (Should interview the object request, some people are aliases)